Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12914594 | 0.91 | NPSR1 (0.61) | NPSR1KMT2AALDH1A1POLBNPC1 | |
| SCHEMBL12914593 | 0.83 | NPSR1 (0.52) | NPSR1KMT2AALDH1A1POLBNPC1 | |
| SCHEMBL3084131 | 0.83 | NPSR1 (0.52) | NPSR1KMT2AALDH1A1POLBNPC1 | |
| SCHEMBL27521078 | 0.81 | L3MBTL1 (0.55) | NPSR1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL1563099 | 0.79 | NPSR1 (0.58) | NPSR1KMT2AALDH1A1POLBNPC1 | |
| SCHEMBL6889531 | 0.77 | NPSR1 (0.56) | NPSR1KMT2AALDH1A1POLBNPC1 | |
| SCHEMBL6503488 | 0.77 | NPSR1 (0.56) | NPSR1KMT2AALDH1A1POLBNPC1 | |
| SCHEMBL4359334 | 0.77 | NPSR1 (0.56) | NPSR1KMT2AALDH1A1POLBNPC1 | |
| SCHEMBL8465476 | 0.77 | NPSR1 (0.56) | NPSR1KMT2AALDH1A1POLBNPC1 | |
| SCHEMBL264029 | 0.77 | NPSR1 (0.56) | NPSR1KMT2AALDH1A1POLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9308244-B2 | Combination therapy using active immunotherapy | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2016-04-12 | — | — | US | disclosed |
| US-20150023993-A1 | COMBINATION THERAPY USING ACTIVE IMMUNOTHERAPY | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| US-20140243339-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140057908-A1 | Method of Treating Cancer | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-1976529-B1 | ANG2 AND VEGF INHIBITOR COMBINATIONS | AMGEN INC (US) | 2013-12-11 | — | — | EP | disclosed |
| EP-2621483-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | Exelixis, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044577-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| EP-1915151-B1 | COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS | AMGEN INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110104161-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. | 2011-05-05 | — | — | US | disclosed |
| EP-2288383-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | Amgen, Inc (US) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009140549-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| EP-1976529-A4 | ANG2 AND VEGF INHIBITOR COMBINATIONS | AMGEN INC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090004213-A1 | COMBINATION THERAPY USING ACTIVE IMMUNOTHERAPY | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2009-01-01 | — | — | US | disclosed |
| EP-1976529-A2 | ANG2 AND VEGF INHIBITOR COMBINATIONS | Amgen Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1915151-A2 | COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS | Amgen, Inc (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007089445-A2 | ANG2 AND VEGF INHIBITOR COMBINATIONS | AMGEN INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006102504-A2 | COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS | AMGEN INC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060216288-A1 | Combinations for the treatment of cancer | AMGEN INC (US) | 2006-09-28 | — | — | US | disclosed |
| US-20020094993-A1 | Compositions for repelling crawling insects | S.C. JOHNSON & SON, INC. | 2002-07-18 | — | — | US | disclosed |
| US-5153223-A | Anticholesterol agents | WARNER-LAMBERT COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104161-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | MET, HGF, HDGF | NPSR1 1322/4885KMT2A 2383/4885ALDH1A1 1646/4885 |
| US-20060216288-A1 | Combinations for the treatment of cancer | TP53, VHL, FOLR2 | NPSR1 3011/4885KMT2A 1732/4885ALDH1A1 588/4885 |
| US-20020094993-A1 | Compositions for repelling crawling insects | ACHE, DDT, GAP43 | NPSR1 1990/4885KMT2A 3439/4885ALDH1A1 1488/4885 |
| US-20140243339-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | MET, HGF, HDGF | NPSR1 1488/4885KMT2A 2288/4885ALDH1A1 1688/4885 |
| US-20140057908-A1 | Method of Treating Cancer | MET, HGF, ACP3 | NPSR1 925/4885KMT2A 708/4885ALDH1A1 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.